NCT02167685

The Chimerix CMX001 Registry

A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 550 (estimated)
• Sponsor: Jazz Pharmaceuticals · Industry
• Sex: All
• Age: 6 Months – 100 Years
• Healthy volunteers: Not accepted

Summary

The prospective observational study is to establish a registry database to evaluate the potential impact of prior treatment with CMX001 on the long-term incidence of specific events, such as outcomes, late CMV and other Double-stranded DNA virus associated events, s well as survival rates in subjects previously enrolled in selected clinical studies of CMX001. Each Registry participant will be followed for a period of approximately 3 years from their enrollment in the Registry.

Conditions

• Outcomes
• Survival Rates

Interventions

Type	Name	Description
DRUG	CMX001

Timeline

• Start date: 2014-01-01
• Primary completion: 2019-05-10
• Completion: 2019-05-10
• First posted: 2014-06-19
• Last updated: 2019-05-17

Locations

51 sites across 3 countries: United States, Belgium, Canada